Endogenous Sterol Metabolites Regulate Growth of EGFR/KRAS-Dependent Tumors via LXR

Endogenous Sterol Metabolites Regulate Growth of EGFR/KRAS-Dependent Tumors via LXR

Meiosis-activating sterols (MAS) are substrates of SC4MOL and NSDHL in the cholesterol pathway and are important for normal organismal development. Oncogenic transformation by epidermal growth factor receptor (EGFR) or RAS increases the demand for cholesterol, suggesting a possibility for metabolic...

Full description

Bibliographic Details
Main Authors:	Linara Gabitova, Diana Restifo, Andrey Gorin, Kunal Manocha, Elizabeth Handorf, Dong-Hua Yang, Kathy Q. Cai, Andres J. Klein-Szanto, David Cunningham, Lisa E. Kratz, Gail E. Herman, Erica A. Golemis, Igor Astsaturov
Format:	Article
Language:	English
Published:	Elsevier 2015-09-01
Series:	Cell Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2211124715008943

Similar Items

EGFR/FOXO3A/LXR-α Axis Promotes Prostate Cancer Proliferation and Metastasis and Dual-Targeting LXR-α/EGFR Shows Synthetic Lethality
by: Tingting Chen, et al.
Published: (2020-11-01)

Sterol-regulated transmembrane protein TMEM86a couples LXR signaling to regulation of lysoplasmalogens in macrophages
by: Suzanne A.E. van Wouw, et al.
Published: (2023-02-01)

Expression of SREBP-1c Requires SREBP-2-mediated Generation of a Sterol Ligand for LXR in Livers of Mice
by: Shunxing Rong, et al.
Published: (2017-02-01)

Preparation of mouse pancreatic tumor for single-cell RNA sequencing and analysis of the data
by: Aizhan Surumbayeva, et al.
Published: (2021-12-01)

NSDHL Depletion Promotes Cellular Senescence in Mouse Embryonic Fibroblasts
by: L.R. Gabitova, et al.
Published: (2015-03-01)

Detection and Analysis of EGFR and KRAS Mutation with Lung Adenocarcinoma
by: Hui ZHANG, et al.
Published: (2015-11-01)

Changes in gene expression associated with loss of function of the NSDHL sterol dehydrogenase in mouse embryonic fibroblasts
by: David Cunningham, et al.
Published: (2005-06-01)

The sterols isolated from evening primrose oil inhibit human colon adenocarcinoma cell proliferation and induce cell cycle arrest through upregulation of LXR
by: S. Montserrat-de la Paz, et al.
Published: (2015-01-01)

A Radiogenomics Ensemble to Predict EGFR and KRAS Mutations in NSCLC
by: Silvia Moreno, et al.
Published: (2021-04-01)

Identfication of Potent LXRβ-Selective Agonists without LXRα Activation by In Silico Approaches
by: Meimei Chen, et al.
Published: (2018-06-01)

PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup.
by: Lei Wang, et al.
Published: (2014-01-01)

Oncogenic KRAS Impairs EGFR Antibodies' Efficiency by C/EBPβ-Dependent Suppression of EGFR Expression
by: Stefanie Derer, et al.
Published: (2012-03-01)

Endogenous Sterol Synthesis Is Dispensable for Trypanosoma cruzi Epimastigote Growth but Not Stress Tolerance
by: Peter C. Dumoulin, et al.
Published: (2022-06-01)

Non-redundant roles for LXRα and LXRβ in atherosclerosis susceptibility in low density lipoprotein receptor knockout mice[S]
by: Eric D. Bischoff, et al.
Published: (2010-05-01)

An essential role for Argonaute 2 in EGFR-KRAS signaling in pancreatic cancer development
by: Sunita Shankar, et al.
Published: (2020-06-01)

Detection and Analysis of EGFR and KRAS Mutations  in the Patients with Lung Squamous Cell Carcinomas
by: Hui ZHANG, et al.
Published: (2015-10-01)

Genomic and transcriptional alterations in lung adenocarcinoma in relation to EGFR and KRAS mutation status.
by: Maria Planck, et al.
Published: (2013-01-01)

LXR agonism for CNS diseases: promises and challenges
by: Ruiyi Zhang, et al.
Published: (2024-04-01)

Foam cell specific LXRα ligand.
by: Radmila Feldmann, et al.
Published: (2013-01-01)

CRE: a cost effective and rapid approach for PCR-mediated concatenation of KRAS and EGFR exons [version 2; referees: 2 approved]
by: Manoj P. Ramteke, et al.
Published: (2016-03-01)

High frequency of KRAS and EGFR mutation profiles in BRAF-negative thyroid carcinomas in Indonesia
by: Heriyanto, Didik Setyo, et al.
Published: (2022)

Pancreatic Adenocarcinoma with Co-Occurrence of KRAS and EGFR Mutations: Case Report and Literature Review
by: Juhi Mody, et al.
Published: (2024-03-01)

An Explainable Radiogenomic Framework to Predict Mutational Status of KRAS and EGFR in Lung Adenocarcinoma Patients
by: Berardino Prencipe, et al.
Published: (2023-06-01)

High frequency of KRAS and EGFR mutation profiles in BRAF-negative thyroid carcinomas in Indonesia
by: Didik Setyo Heriyanto, et al.
Published: (2022-12-01)

Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy
by: Li Kuiyuan, et al.
Published: (2009-04-01)

Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations
by: Roberto Ruiz-Cordero, et al.
Published: (2020-01-01)

Pathological Factors Affecting DNA Quality in BRAF, EGFR, and KRAS Gene Molecular Tests
by: Hyon-Goo Yun, et al.
Published: (2020-12-01)

An anti-EGFR × cotinine bispecific antibody complexed with cotinine-conjugated duocarmycin inhibits growth of EGFR-positive cancer cells with KRAS mutations
by: Junyeong Jin, et al.
Published: (2018-05-01)

Regulation of type 1 iodothyronine deiodinase by LXRα.
by: Yoriko Sakane, et al.
Published: (2017-01-01)

LXR regulate cholesterol homeostasis in the proximal mouse epididymis.
by: Jean-Marc A Lobaccaro, et al.
Published: (2010-01-01)

Synthetic LXR agonists increase LDL in CETP species
by: Pieter H.E. Groot, et al.
Published: (2005-10-01)

LXR-mediated inhibition of CD4+ T helper cells.
by: Laura A Solt, et al.
Published: (2012-01-01)

Selenite as a dual apoptotic and ferroptotic agent synergizes with EGFR and KRAS inhibitors with epigenetic interference
by: Lok Seng Chan, et al.
Published: (2023-03-01)

Mutational landscape of EGFR-, MYC-, and Kras-driven genetically engineered mouse models of lung adenocarcinoma
by: Politi, Katerina, et al.
Published: (2017)

Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma
by: Arun M Unni, et al.
Published: (2015-06-01)

Pyrosequencing data analysis software: a useful tool for EGFR, KRAS, and BRAF mutation analysis
by: Shen Shanxiang, et al.
Published: (2012-05-01)

EGFR, HER-2 and KRAS in canine gastric epithelial tumors: a potential human model?
by: Rossella Terragni, et al.
Published: (2014-01-01)

AMPK activation overcomes anti-EGFR antibody resistance induced by KRAS mutation in colorectal cancer
by: Hua Ye, et al.
Published: (2020-07-01)

132 CAR macrophages (CAR-M) elicit a systemic anti-tumor immune response and synergize with PD1 blockade in immunocompetent mouse models of HER2+ solid tumors
by: Michael Klichinsky, et al.
Published: (2020-11-01)

The stimulatory effect of LXRα is blocked by SHP despite the presence of a LXRα binding site in the rabbit CYP7A1 promoter
by: Quan Shang, et al.
Published: (2006-05-01)